Back pain in elderly patients with locomotive syndrome: Focus on efficacy and safety

Back and joint pain occur in 70% of patients aged 60 years and older. The presence of arterial hypertension (AH), cerebrovascular diseases (strokes, heart attacks, chronic heart failure, ischemic heart disease), diabetes mellitus create significant obstacles to the choice of therapy. In 2007, the term “locomotive syndrome” (LS) appeared in world practice, proposed by the Japanese Orthopedic Association to characterize elderly patients with unstable balance, a tendency to fall, due to structural and functional damage to the organs of the nervous and musculoskeletal systems. Chronic musculoskeletal pain in LS has a number of features, such as minor severity (constant nature, exacerbations associated with blood pressure fluctuations). The presence of cognitive impairment complicates the assessment of the severity of pain syndrome, but at the same time triggers a cascade of neuropsychiatric symptoms (anxiety, depressive mood). The problem of treating geriatric patients with LS is a complex task, but knowledge of the basic principles allows you to avoid mistakes in choosing drug therapy and adequately add other non-drug regimens. All patients over 65 years old with chronic pain should be screened for cognitive impairment, anxiety and depression. These syndromes themselves can worsen the patient’s condition and make pain therapy ineffective. Evaluation of the drugs used, especially for pain relief, should be carried out taking into account drug interactions. Compliance with simple rules will help reduce the severity of symptoms, improve functioning and quality of life. Among NSAIDs, preference should be given to the safest ones, having minimal cardiac risks, not causing deterioration in cognitive functions and falling syndrome.

1. Leopoldino AAO, Diz JBM, Martins VT, Henschke N, Pereira LSM, Dias RC et al. Prevalence of low back pain in older Brazilians: a systematic review with meta-analysis. Rev Bras Reumatol Engl Ed. 2016;56(3):258–269. https://doi.org/10.1016/j.rbr.2016.01.004.

2. GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508–e522. https://doi.org/10.1016/S2665-9913(23)00163-7.

3. Traeger AC, Underwood M, Ivers R, Buchbinder R. Low back pain in people aged 60 years and over. BMJ. 2022;376:e066928. https://doi.org/10.1136/bmj-2021-066928.

4. Dagnino APA, Campos MM. Chronic Pain in the Elderly: Mechanisms and Perspectives. Front Hum Neurosci. 2022;16:736688. https://doi.org/10.3389/fnhum.2022.736688.

5. Putilina MV. Risk factors, features of clinical course and treatment approaches in aged patients with cerebral stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2011;111(5):90–95. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-skorsakova/2011/5/031997-72982011518.

6. Tesarz J, Eich W, Baumeister D, Kohlmann T, D’Agostino R, Schuster AK. Widespread pain is a risk factor for cardiovascular mortality: results from the Framingham Heart Study. Eur Heart J. 2019;40(20):1609–1617. https://doi.org/10.1093/eurheartj/ehz111.

7. Mensah GA, Fuster V, Murray CJL, Roth GA; Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990–2022. J Am Coll Cardiol. 2023;82(25):2350–2473. https://doi.org/10.1016/j.jacc.2023.11.007.

8. Lo K, Au M, Ni J, Wen C. Association between hypertension and osteoarthritis: A systematic review and meta-analysis of observational studies. J Orthop Translat. 2021;32:12–20. https://doi.org/10.1016/j.jot.2021.05.003.

9. Ching K, Houard X, Berenbaum F, Wen C. Hypertension meets osteoarthritis – revisiting the vascular aetiology hypothesis. Nat Rev Rheumatol. 2021;17(9):533–549. https://doi.org/10.1038/s41584-021-00650-x.

10. Putilina MV. Current concepts about small vessel disease. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(11):65–73. (In Russ.) https://doi.org/10.17116/jnevro201911911165.

11. Franceschi C, Campisi J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J Gerontol A Biol Sci Med Sci. 2014;69(Suppl. 1):4–9. https://doi.org/10.1093/gerona/glu057.

12. Naumov AV, Vorobyeva NM, Khovasova NO, Moroz VI, Meshkov AD, Manevich TM et al. The prevalence of osteoarthritis and its association with geriatric syndromes in people over 65: data from the Russian epidemiological study EVKALIPT. Terapevticheskii Arkhiv. 2021;93(12):1482–1490. (In Russ.) https://doi.org/10.26442/00403660.2021.12.201268.

13. Chaplin WJ, McWilliams DF, Millar BS, Gladman JRF, Walsh DA. The bidirectional relationship between chronic joint pain and frailty: data from the Investigating Musculoskeletal Health and Wellbeing cohort. BMC Geriatr. 2023;23(1):273. https://doi.org/10.1186/s12877-023-03949-4.

14. Putilina MV, Teplova NV, Lila AM, Zagorodniy NV. Locomotive syndrome: from paradigms to clinical reality. Terapevticheskii Arkhiv. 2021;93(5):613–621. (In Russ.) https://doi.org/10.26442/00403660.2021.05.200798.

15. Ikemoto T, Arai YC. Locomotive syndrome: clinical perspectives. Clin Interv Aging. 2018;13:819–827. https://doi.org/10.2147/CIA.S148683.

16. Wallwork SB, Braithwaite FA, O’Keeffe M, Travers MJ, Summers SJ, Lange B et al. The clinical course of acute, subacute and persistent low back pain: a systematic review and meta-analysis. CMAJ. 2024;196(2):E29-E46. https://doi.org/10.1503/cmaj.230542.

17. Putilina MV, Baranova OA. Results of the multicenter clinical and epidemiological observational program “GLOBUS” (determination of the prevalence of dizziness and assessment of therapy regimens at the outpatient level). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2014;114(5):33–38. (In Russ.) Available at: https://www.mediasphera.ru/issues/zhurnal-nevrologii-i-psikhiatrii-im-s-s-korsakova/2014/5/0319977298201456.

18. Dell’Isola A, Pihl K, Turkiewicz A, Hughes V, Zhang W, Bierma-Zeinstra S et al. Risk of Comorbidities Following Physician-Diagnosed Knee or Hip Osteoarthritis: A Register-Based Cohort Study. Arthritis Care Res. 2022;74(10):1689–1695. https://doi.org/10.1002/acr.24717.

19. Herrero-Beaumont G, Castro-Dominguez F, Migliore A, Naredo E, Largo R, Reginster JY. Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clin Exp Res. 2024;36(1):45. https://doi.org/10.1007/s40520-024-02714-w.

20. Putilina MV, Teplova NV, Gerasimova OS. The concept of syndromic diagnoses of osteoarthritis and back pain as a cause of therapy failure. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2021;14(3):407–414. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2021.104.

21. Ribeiro H, Rodrigues I, Napoleão L, Lira L, Marques D, Veríssimo M et al. Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features. Biomed Pharmacother. 2022;150:112958. https://doi.org/10.1016/j.biopha.2022.112958.

22. Ozleyen A, Yilmaz YB, Donmez S, Atalay HN, Antika G, Tumer TB. Looking at NSAIDs from a historical perspective and their current status in drug repurposing for cancer treatment and prevention. J Cancer Res Clin Oncol. 2023;149(5):2095–2113. https://doi.org/10.1007/s00432-022-04187-8.

23. Domenichiello AF, Ramsden CE. The silent epidemic of chronic pain in older adults. Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:284–290. https://doi.org/10.1016/j.pnpbp.2019.04.006.

24. Syraeva GI, Kolbin AS, Mishinova SA, Kalyapin AA. Quantitative and qualitative evaluation of the use of nonsteroidal anti-inflammatory drugs in the Russian Federation over 10 years. Kachestvennaya Klinicheskaya Praktika. 2022;(3):19–30. (In Russ.) https://doi.org/10.37489/2588-0519-2022-3-19-30.

25. Oganov RG, Simanenkov VI, Bakulin IG, Bakulina NV, Barbarash OL, Boytsov SA et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5–66. (In Russ.) https://doi.org/10.15829/1728-8800-2019-1-5-66.

26. Putilina MV, Mutovina ZYu, Kurushina OV, Khalilova DM, Saverskaya EN, Stepanova SB et al. Determination of the prevalence of postcovid syndrome and assessment of the effectiveness of the drug Cortexin in the treatment of neurological disorders in patients with postcovid syndrome. Results of the multicenter clinical and epidemiological observational program CORTEX. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2022;122(1):84–90. (In Russ.) https://doi.org/10.17116/jnevro202212201184

27. Yamada K, Kubota Y, Tabuchi T. A prospective study of knee pain, low back pain, and risk of dementia: the JAGES project. Sci Rep. 2019;9(1):10690. https://doi.org/10.1038/s41598-019-47005-x.

28. Lila AM, Tkacheva ON, Yakhno NN, Naumov AV, Alekseeva LI, Kotovskaya YV et al. Comprehensive approach to the choice of therapy in patients with osteoarthritis at the first visit to the doctor. Expert consensus (literature review and resolution). Sovremennaya Revmatologiya. 2021;15(3):111–116. (In Russ.) https://doi.org/10.14412/1996-7012-2021-3-111-116.

29. Zhang Y, Wang Y, Zhao C, Cai W, Wang Z, Zhao W. Effects of blood pressure and antihypertensive drugs on osteoarthritis: a mendelian randomized study. Aging Clin Exp Res. 2023;35(11):2437–2444. https://doi.org/10.1007/s40520-023-02530-8.

30. Atkinson RJ. Gait analysis can help with low back pain in people aged 60 years and over. BMJ. 2022;377:o1059. https://doi.org/10.1136/bmj.o1059.

31. Ushkalova EA, Tkacheva ON, Runikhina NK, Chukhareva NA, Bevz AYu. Features of pharmacotherapy in the elderly patients. Introduction to the problem. Rational Pharmacotherapy in Cardiology. 2016;12(1):94–100. (In Russ.) https://doi.org/10.20996/1819-6446-2016-12-1-94-100.

32. Putilina MV, Teplova NV. Drug safety as a priority area of domestic medicine. Lechebnoe Delo. 2019;(4):7–14. (In Russ.) https://doi.org/10.24411/2071-5315-2019-12152.

33. Lee Y, Kim J, Chon D, Lee KE, Kim JH, Myeong S, Kim S. The effects of frailty and cognitive impairment on 3-year mortality in older adults. Maturitas. 2018;107:50–55. https://doi.org/10.1016/j.maturitas.2017.10.006.

34. Ramanathan S, Hibbert P, Wiles L, Maher CG, Runciman W. What is the association between the presence of comorbidities and the appropriateness of care for low back pain? A population-based medical record review study. BMC Musculoskelet Disord. 2018;19(1):391. https://doi.org/10.1186/s12891-018-2316-z.

35. Putilina MV. Fixed combination of non-steroidal anti-inflammatory drug and muscle relaxant as the basis for rational therapy of pain syndromes: A review. Terapevticheskii Arkhiv. 2024;96(2):176–180. (In Russ.) https://doi.org/10.26442/00403660.2024.02.202583.

36. Levin OS, Moseykin IA, Kazakova TV, Grishin DV, Putilina MV, Sadovy IV et al. Efficiency of alflutop in vertebrogenic cervicobrachialgia. Farmateka, 2008;(6):52–59. (In Russ.) Available at: https://pharmateca.ru/ru/archive/edition/1146.

37. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly. Aging Dis. 2018;9(1):143–150. https://doi.org/10.14336/AD.2017.0306.

38. Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. https://doi.org/10.1136/bmj.c7086.

39. Parfenov VA. Therapeutic outcomes in patients with acute non-specific (musculoskeletal) pain according to the FORTE (ФОРТЕ) observational study. Neurology, Neuropsychiatry, Psychosomatics. 2024;16(3):88–95. (In Russ.) https://doi.org/10.14412/2074-2711-2024-3-88-95.

40. Karateev AE, Nasonov EL, Ivashkin VT, Martynov AI, Yakhno NN, Arutyunov GP et al. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Rheumatology Science and Practice. 2018;56(Suppl. 1):1–29. (In Russ.) https://doi.org/10.14412/1995-4484-2018-1-29.

41. McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388. https://doi.org/10.1371/journal.pmed.1001388.

42. Brutzkus JC, Shahrokhi M, Varacallo MA. Naproxen. 2023 Aug 4. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK525965.

43. Jung SY, Jang EJ, Nam SW, Kwon HH, Im SG, Kim D et al. Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysis. Mod Rheumatol. 2018;28(6):1021–1028. https://doi.org/10.1080/14397595.2018.1439694.

44. Davies NM, Anderson KE. Clinical pharmacokinetics of naproxen. Clin Pharmacokinet. 1997;32(4):268–293. https://doi.org/10.2165/00003088-199732040-00002.

45. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627): 1854–1860. https://doi.org/10.1016/S0140-6736(08)60799-0.

46. Levin OS, Skoromets AA, Tabeeva GR, Doronina OB, Shirokov VA, Trinitatsky YuV et al. The efficacy and safety of naproxen in the treatment of nonspecific lumbalgia: the results of an open multi-center study (NEST). Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 2019;119(5):27–31. (In Russ.) https://doi.org/10.17116/jnevro201911905127.

47. Putilina MV, Teplova NV, Chervyakova GA, Eryomina YuN. Basic paradigms of antidepressants use in real clinical practice. Medical Alphabet. 2020;(33):5–12. (In Russ.) https://doi.org/10.33667/2078-5631-2020-33-5-12.

48. Hirase T, Hirase J, Ling J, Kuo PH, Hernandez GA, Giwa K, Marco R. Duloxetine for the Treatment of Chronic Low Back Pain: A Systematic Review of Randomized Placebo-Controlled Trials. Cureus. 2021;13(5):e15169. https://doi.org/10.7759/cureus.15169.

49. Sakai Y, Morita Y, Kawai K, Fukuhara J, Ito T, Yamazaki K et al. Targeted vibratory therapy as a treatment for proprioceptive dysfunction: Clinical trial in older patients with chronic low back pain. PLoS ONE. 2024;19(7):e0306898. https://doi.org/10.1371/journal.

50. Putilina MV. Modern ideas about the therapy of anxiety-depressive disorders in chronic cerebral ischemia. RMJ. 2011;(9):569–573. (In Russ.) Available at: https://www.rmj.ru/articles/nevrologiya/Sovremennye_predstavleniya_o_terapii_trevoghnodepressivnyh_rasstroystv_pri_hronicheskoy_ishemii_golovnogo_mozga/.